Publications & Presentations

  • Kaur S, Wang L, Nawabit R, Highland K, Hill N, Mehra R and the Pulmonary Vascular Disease Phenomics (PVDOMICS) Study Group. Sleep disordered breathing and cardiopulmonary indices in World Symposium of Pulmonary Hypertension Group 1 Pulmonary Hypertension. 33rd Annual Meeting of the Associated Professional Sleep Societies, San Antonio, TX, June 8-12, 2019
  • Hemnes AR, Horn EM, Rosenzweig EB, Leopold J, Hu B and Barnard J, PVDOMICS Investigators. A preliminary foray of proteomic clustering in PVDOMICS. Aspen Lung Conference, Aspen Colorado, June 5-8, 2019
  • Rischard FP on behalf of the PVDOMICS Study Group. Insights from the Pulmonary Vascular Phenomics Project (PVDOMICS): The effect of multiple pulmonary vascular groups on hemodynamics in pulmonary hypertension. American Thoracic Society Conference, Dallas, TX, May 17-22, 2019
  • Mehra R, Wang L, Nawabit R, Kaur S, Highland K, Hill N and the PVDOMICS Study Group. Sleep Disordered breathing phenotypes across WSPH pulmonary hypertension groups: Insights from the Pulmonary Vascular Disease Phenomics Study. American Thoracic Society Conference, Dallas, TX, May 17-22, 2019.
  • Horn E and the PVDOMICS Study Group. PVDOMICS: World Symposium Classification (WSPH) Group 1 vs mixed WSPH Group 1 disease: splitters or lumpers. American Thoracic Society Conference, Dallas, TX, May 17-22, 2019.
  • Hemnes AR and the PVDOMICS Study Group. PVDOMICS: Early clinical findings across the spectrum of pulmonary hypertension. American Thoracic Society Conference, Dallas, TX, May 17-22, 2019
  • Mehra R. Sleep disordered breathing and pulmonary hypertension across the WHO Categories: novel findings from the PVDOMICS study. American Thoracic Society Conference, Dallas, TX, May 17-22, 2019
  • Lempel J. Radiomics in pulmonary hypertension: What we have learned from PVDOMICS? American Thoracic Society Conference, Dallas, TX, May 17-22, 2019
  • Barnard J. Cluster analysis of pulmonary hypertension patients in PVDOMICS using extensive multi-layered clinical phenotypes. American Thoracic Society Conference, Dallas, TX, May 17-22, 2019
  • Aldred M. Novel proteomics and genomics findings in pulmonary hypertension patients from PVDOMICS study. American Thoracic Society Conference, Dallas, TX, May 17-22, 2019
  • Berman-Rosenzweig E. Progress in PH Serum Biomarker Discovery: Insights from PVDOMICS. American College of Cardiology Meetings, New Orleans, Louisiana, March 16-18, 2019
  • Leopold J on behalf of the PVDOMICS investigators. New Discoveries on the Metabolic Basis of PAH: Insights from the NHLBI Pulmonary Vascular Disease Phenomics (PVDOMICS) Study. American College of Cardiology Meetings, New Orleans, Louisiana, March 16-18, 2019
  • Hemnes A. PVDOMICS Update. PAH ICON, Barcelona, Spain, February 4-5, 2019
  • Rischard FP, Kwon D, Vanderpool R, Jellis C, Park M, Radeva M, Frantz RP and the PVDOMICS Study Group. Severity of RV Dysfunction in Pulmonary Vascular Disease across WSPH Groups: Initial Results from the Pulmonary Vascular Phenomics Study (PVDOMICS). 13th Pulmonary Vascular Research Institute Annual World Congress on Pulmonary Vascular Disease, Barcelona, Spain, January 30-February 3, 2019
  • Leopold J on behalf of the PVDOMICS investigators. The NHLBI Pulmonary Vascular Disease Phenomics (PVDOMICS) Study. 13th Pulmonary Vascular Research Institute Annual World Congress on Pulmonary Vascular Disease, Barcelona, Spain, January 30-February 3, 2019
  • Tang W. Overview of the NHLBI PVDOMICS Study. Scientific Session, American Heart Association, Chicago, IL, November 10-14, 2018.
  • Rischard F. Novel findings from hemodynamic analyses and Cardiopulmonary Exercise Testing (CPET). Scientific Session, American Heart Association, Chicago, IL, November 10-14, 2018
  • Leopold JA. Metabolomic profiling identifies subgroups of patients with PH. Scientific Session, American Heart Association, Chicago, IL, November 10-14, 2018.
  • Horn E. Clinical characterization of PH patients, disease comparators, and healthy controls enrolled in PVDOMICS. Scientific Session, American Heart Association, Chicago, IL, November 10-14, 2018
  • Hemnes A. Analyzing the proteome to re-categorize patients with PH. Scientific Session, American Heart Association, Chicago, IL, November 10-14, 2018.
  • Frantz RP. Non-invasive imaging (echo, MRI) defines RV structural and functional differences in PVDOMICS participants. Scientific Session, American Heart Association, Chicago, IL, November 10-14, 2018.
  • Hemnes, A. The NHLBI PVDOMICS initiative: an introduction. Pulmonary Hypertension Association’s International Pulmonary Hypertension Conference and Scientific Sessions, Orlando, FL, June 29-July 1, 2018.
  • Li L, Hu B, Willard, B. Proteomic profiling of plasma samples from pulmonary hypertension patients using label-free quantitation and isobaric tagging on depleted and non-depleted samples. American Society Mass Spectrometry, San Diego, CA, June 3-7, 2018.
  • Leopold J. PVDOMICS session: Initial findings from the NHLBI PVDOMICS program: deep phenotyping of patients with pulmonary hypertension. PVDOMICS metabolomics characterization/Introduction of the new metabolomics findings in PVDOMICS patients. American Thoracic Society Conference, San Diego, CA, May 18-23, 2018.
  • Frantz R. PVDOMICS session, Initial findings from the NHLBI PVDOMICS program: deep phenotyping of patients with pulmonary hypertension. PVDOMICS imaging (Echo, MRI) findings/Introduction of the new imaging findings using echocardiography and MRI in PVDOMICS patients. American Thoracic Society Conference, San Diego, CA, May 18-23, 2018.
  • Rischard F. PVDOMICS session, Initial findings from the NHLBI PVDOMICS program: deep phenotyping of patients with pulmonary hypertension. PVDOMICS exercise (CPET, RHC) findings/Introduction of the new exercise findings using CPET and RHC in PVDOMICS patients. American Thoracic Society Conference, San Diego, CA, May 18-23, 2018.
  • Horn E. PVDOMICS session, Initial findings from the NHLBI PVDOMICS program: deep phenotyping of patients with pulmonary hypertension. Overall summary of PVDOMICS participants/Introduction of the overall PVDOMICS program and its patient’s demographics and characteristics. American Thoracic Society Conference, San Diego, CA, May 18-23, 2018.
  • Leopold, J. From precision biology to precision medicine in pulmonary hypertension: revolutionizing healthcare through revolutionary science. Stanford PVD 4th International Symposium, Palo Alto, CA, May 18, 2018.
  • Rischard F. Scientific session, Initial findings from the NHLBI PVDOMICS program: deep phenotyping of patients with pulmonary hypertension. Use of a new predictive equation for oxygen consumption in adults with pulmonary hypertension undergoing cardiac catherization. Society for Cardiovascular Angiography and Interventions, San Diego, CA, April 25-28, 2018.
  • Hemnes A, Horn E. DEBATE: Gene vs. product: genetic testing and not proteomics is the path forward to realize personalized management of PAH. International Society for Heart and Lung Transplantation (ISHLT), Nice, France, April 11-14, 2018.
  • Leopold, J. The NHLBI pulmonary vascular disease phenomics (PVDOMICS) study: a precision medicine approach to pulmonary hypertension. 12th Pulmonary Vascular Research Institute Annual World Congress on Pulmonary Vascular Disease, Singapore, January 21-25, 2018.
  • Berman-Rosenzweig E. What can we expect to learn from the NHLBI PVDOMICS initiative. Chest Annual Meeting, Toronto, Canada, October 28-November 1, 2017.
  • Erickson H, Hansen L, Rischard F. Clinically important pulmonary vascular phenotypes across the current WHO categorization: the PVDOMICS project. 2017 PH Professional Network (PHPN) Symposium, North Bethesda, MD, October 5-7, 2017.
  • Leopold J. Endothelial cell signatures in pulmonary hypertension. Heart Failure Society of America, 21st Annual Scientific Meeting, Dallas, TX, September 16-19, 2017.
  • Mathai S. Phenotype based therapies in PH: looking beyond WHO Class. Heart Failure Society of America, 21st Annual Scientific Meeting, Dallas, TX, September 16-19, 2017.
  • Berman-Rosenzweig E. Genomic determinants of pulmonary hypertension. Heart Failure Society of America, 21st Annual Scientific Meeting, Dallas, TX, September 16-19, 2017.
  • Abidov A. Cardiac imaging phenotypes of pulmonary hypertension. Heart Failure Society of America, 21st Annual Scientific Meeting, Dallas, TX, September 16-19, 2017.
  • Aldred M. Integrative genomics analyses in PAH. PVDOMICS Session, American Thoracic Society Conference, Washington DC, May 19-24, 2017.
  • Mathai S. PROs in PH: leveraging PVDOMICS to understand the patient perspective. PVDOMICS Session, American Thoracic Society Conference, Washington DC, May 19-24, 2017.
  • Hill N. Overview of NHLBI PVDOMICS program and initial progress report. PVDOMICS Session, American Thoracic Society Conference, Washington DC, May 19-24, 2017.
  • Newman JH. The PVDOMICS network study: improved understanding though deep phenotyping. Mexican Society of Pneumology and Thoracic Surgery, Puebla, Mexico, April 17-21, 2017.
  • Hassoun PM. NHLBI pulmonary vascular disease phenomics (PVDOMICS) study design and updates. American College of Cardiology Meetings, Washington DC, March 17-19, 2017.
  • Tang W. The NIH/NHLBI PVDOMICS study design and overview. American Heart Association Meetings, New Orleans, LA, November 12-16, 2016.
  • Hill N. NHLBI PVDOMICS Program Overview: Enhanced Phenotyping of Pulmonary Vascular Diseases. Scientific Leadership Council of the Pulmonary Hypertension Association. Washington, DC. September 30, 2016.
  • Newman J. NHLBI Pulmonary Vascular Disease Phenomics (PVDOMICS) Program: Study design and updates. American Thoracic Society Conference, San Francisco, CA, May 13-18, 2016.
  • Erzurum S. NHLBI Pulmonary Vascular Disease Phenomics (PVDOMICS) Program: Overview. American Thoracic Society Conference, San Francisco, CA, May 13-18, 2016.

NHLBI Pulmonary Vascular Disease Phenomics Program


Funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health with support from the Pulmonary Hypertension Association